Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 1
2010 1
2012 6
2013 11
2014 12
2015 13
2016 17
2017 9
2018 14
2019 17
2020 14
2021 23
2022 14
2023 13
2024 14
2025 18

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

173 results

Results by year

Filters applied: . Clear all
Page 1
Clinical features of neuroendocrine prostate cancer.
Conteduca V, Oromendia C, Eng KW, Bareja R, Sigouros M, Molina A, Faltas BM, Sboner A, Mosquera JM, Elemento O, Nanus DM, Tagawa ST, Ballman KV, Beltran H. Conteduca V, et al. Eur J Cancer. 2019 Nov;121:7-18. doi: 10.1016/j.ejca.2019.08.011. Epub 2019 Sep 13. Eur J Cancer. 2019. PMID: 31525487 Free PMC article.
Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer.
Puca L, Gavyert K, Sailer V, Conteduca V, Dardenne E, Sigouros M, Isse K, Kearney M, Vosoughi A, Fernandez L, Pan H, Motanagh S, Hess J, Donoghue AJ, Sboner A, Wang Y, Dittamore R, Rickman D, Nanus DM, Tagawa ST, Elemento O, Mosquera JM, Saunders L, Beltran H. Puca L, et al. Among authors: conteduca v. Sci Transl Med. 2019 Mar 20;11(484):eaav0891. doi: 10.1126/scitranslmed.aav0891. Sci Transl Med. 2019. PMID: 30894499 Free PMC article. Clinical Trial.
Immunogenomic Landscape of Neuroendocrine Prostate Cancer.
Bhinder B, Ferguson A, Sigouros M, Uppal M, Elsaeed AG, Bareja R, Alnajar H, Eng KW, Conteduca V, Sboner A, Mosquera JM, Elemento O, Beltran H. Bhinder B, et al. Among authors: conteduca v. Clin Cancer Res. 2023 Aug 1;29(15):2933-2943. doi: 10.1158/1078-0432.CCR-22-3743. Clin Cancer Res. 2023. PMID: 37223924 Free PMC article.
Taxane-related nail toxicity.
Schepisi G, Conteduca V, Lolli C, Medri M, De Giorgi U. Schepisi G, et al. Among authors: conteduca v. Lancet Oncol. 2015 Jul;16(7):e310-1. doi: 10.1016/S1470-2045(15)00019-4. Lancet Oncol. 2015. PMID: 26149877 No abstract available.
Biological Evolution of Castration-resistant Prostate Cancer.
Davies A, Conteduca V, Zoubeidi A, Beltran H. Davies A, et al. Among authors: conteduca v. Eur Urol Focus. 2019 Mar;5(2):147-154. doi: 10.1016/j.euf.2019.01.016. Epub 2019 Feb 14. Eur Urol Focus. 2019. PMID: 30772358 Review.
Epigenetics in prostate cancer: clinical implications.
Conteduca V, Hess J, Yamada Y, Ku SY, Beltran H. Conteduca V, et al. Transl Androl Urol. 2021 Jul;10(7):3104-3116. doi: 10.21037/tau-20-1339. Transl Androl Urol. 2021. PMID: 34430414 Free PMC article. Review.
Plasma Androgen Receptor in Prostate Cancer.
Conteduca V, Gurioli G, Brighi N, Lolli C, Schepisi G, Casadei C, Burgio SL, Gargiulo S, Ravaglia G, Rossi L, Altavilla A, Farolfi A, Menna C, Colangione SP, Pulvirenti M, Romeo A, De Giorgi U. Conteduca V, et al. Cancers (Basel). 2019 Nov 4;11(11):1719. doi: 10.3390/cancers11111719. Cancers (Basel). 2019. PMID: 31689899 Free PMC article. Review.
Immunotherapy for Prostate Cancer: Where We Are Headed.
Schepisi G, Farolfi A, Conteduca V, Martignano F, De Lisi D, Ravaglia G, Rossi L, Menna C, Bellia SR, Barone D, Gunelli R, De Giorgi U. Schepisi G, et al. Among authors: conteduca v. Int J Mol Sci. 2017 Dec 5;18(12):2627. doi: 10.3390/ijms18122627. Int J Mol Sci. 2017. PMID: 29206214 Free PMC article. Review.
173 results